Coronavirus company news summary – ZandCell launches saliva based coronavirus test – FUJIFILM Sonosite and CHEST Foundation announce joint grant for Covid-19 research

16 September 2020 (Last Updated September 16th, 2020 09:46)

Thermo Fisher Scientific has announced an investment of over $140m to expand its laboratory plastics consumables production to support demand for Covid-19 testing, besides development and manufacturing of therapies and vaccines. Among the Thermo Fisher sites being expanded are Rochester in New York; Petaluma, California; Monterrey and Tijuana of Mexico; and Joensuu in Finland.

Innatoss Laboratories has announced a neutralising antibody public testing service against SARS-CoV-2 in Europe, using GenScript's cPass SARS-CoV-2 Neutralization Antibody Detection Kit. This kit is claimed to be the first in the world to allow quick detection of neutralizing antibodies (NAbs), the particular specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service of this kind for the public.

ZandCell, a biotechnology firm, has launched the saliva-based ZandCell COVID-19 Rapid Antigen Test. This kit is available in large quantities to be used in airports, governments, cities, hospitals, healthcare workers and, sports events, to quickly and effectively test patients for the infectious virus and provide immediate results within a few minutes.

FUJIFILM Sonosite, a provider of point-of-care ultrasound (POCUS) solutions, and the CHEST Foundation, the charitable foundation of the American College of Chest Physicians, have announced joint grant in creating the CHEST Foundation Research Grant in Ultrasonography and COVID-19. The aim of this grant is to look into the role of POCUS technology on COVID-19 patients through clinical research.